The FDA has removed the recommended pause in the use of Valneva’s chikungunya vaccine Ixchiq in individuals aged 60 years and older.

The FDA had halted use in older adults while it investigated reports of side effects. The vaccine’s label now carries new ...

The FDA has removed a pause in the use of Valneva’s chikungunya vaccine in older adults while tweaking the shot’s label with ...

Ixchiq now has a warning about its use among elderly people with multiple underlying health conditions after postmarketing ...

Valneva SE ( NASDAQ: VALN) said on Thursday that the FDA has lifted its pause on the use of its chikungunya vaccine, Ixchiq, ...

The US Food and Drug Administration (FDA) has lifted a pause in the use of Valneva’s chikungunya vaccine Ixchiq in older ...

1FDA Accepts Valneva’s Chikungunya Vaccine License Application for Priority Review - Valneva2Valneva Announces PDUFA Date Extension for Chikungunya Virus Vaccine Candidate - Valneva3 This ...

18 Valneva Announces Publication of its Chikungunya Vaccine Candidate Phase 3 Data in The Lancet - Valneva 19 Valneva and Instituto Butantan Sign Final Agreement on Single-Shot Chikungunya Vaccine ...

Valneva has been responding to the French government’s call for vaccine supply of IXCHIQ ® in La Reunion 1 as the island is going through a major chikungunya outbreak with ~ 40,000 confirmed ...

In January, Valneva reported Phase 3 data in adolescents for its single-shot chikungunya virus vaccine. The vaccine showed a 98.3% sero-response rate one year after the single vaccination.

6 Valneva and Instituto Butantan Sign Final Agreement on Single-Shot Chikungunya Vaccine for Low and Middle Income Countries 7 CEPI awards up to $23.4 million to Valneva for late-stage development ...

Valneva's Q3 financial results exceeded expectations, indicating a strong operational performance. The FDA approval of Valneva's chikungunya vaccine, Ixchiq, adds substantial value to the company ...